Evaluation of algorithms for the diagnostic assessment and the reentry of blood donors who tested reactive for antibodies against hepatitis B core antigen

Transfusion

Volumn 51, Issue 7, 2011, Pages 1477-1485

  Juhl, David ^a   Luhm, Jürgen ^a   Görg, Siegfried ^a   Ziemann, Malte ^a   Hennig, Holger ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B CORE ANTIBODY; HEPATITIS B CORE ANTIGEN; VIRUS DNA;

ALGORITHM; ARTICLE; BLOOD DONOR; CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY; FOLLOW UP; HEPATITIS B VIRUS; HUMAN; IMMUNOASSAY; NONHUMAN;

ALGORITHMS; BLOOD DONORS; DIAGNOSIS, COMPUTER-ASSISTED; DIAGNOSTIC ERRORS; FALSE POSITIVE REACTIONS; HEPATITIS B ANTIBODIES; HEPATITIS B CORE ANTIGENS; HUMANS; IMMUNOASSAY; RETROSPECTIVE STUDIES;

EID: 79960195167     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2010.03031.x     Document Type: Article

References (33)

1. Comanor L, Holland P,. Hepatitis B virus blood screening: unfinished agendas. Vox Sang 2006; 91: 1-12. (Pubitemid 43822298)
2. Keller-Stanislawski B, Lohmann A, Günay S, Heiden M, Funk MB,. The German haemovigilance system - reports of serious adverse transfusion reactions between 1997 and 2007. Transfus Med 2009; 19: 340-9.
3. Niederhauser C, Weingand T, Candotti D, Maier A, Tinguely C, Wuillemin WA, Gowland P, Allain JP, Stolz M,. Fatal outcome of a hepatitis B virus transfusion-transmitted infection. Vox Sang 2010; 98: 504-7.
4. Soldan K, Barbara JA, Dow BC,. Transfusion-transmitted hepatitis B virus infection in the UK: a small and moving target. Vox Sang 2002; 83: 305-8. (Pubitemid 35434351)
5. Mühlbacher A, Zdunek D, Melchior W, Michl U,. Is infective blood donation missed without screening for antibody to hepatitis B core antigen and/or hepatitis B virus DNA? Vox Sang 2001; 81: 139. (Pubitemid 35369993)
6. Allain JP,. Occult hepatitis B virus infection: implications in transfusion. Vox Sang 2004; 86: 83-91.
7. Gerlich WH,. Diagnostic problems caused by HBsAg mutants - a consensus report of an expert meeting. Intervirology 2004; 47: 310-3. (Pubitemid 39541276)
8. Allain JP, Hewitt PE, Tedder RS, Williamson LM,. Evidence that anti-HBc but not HBV DNA testing may prevent some HBV transmission by transfusion. Br J Haematol 1999; 107: 186-95. (Pubitemid 29500825)
9. Hennig H, Puchta I, Luhm J, Schlenke P, Goerg S, Kirchner H,. Frequency and load of hepatitis B virus DNA in first-time blood donors with antibodies to hepatitis B core antigen. Blood 2002; 100: 2637-41.
10. Soldan K, Ramsay M, Collins M,. Acute hepatitis B infection associated with blood transfusion in England and Wales, 1991-7: review of database. BMJ 1999; 318: 95. (Pubitemid 29188926)
11. Food and Drug Administration. Center for Biologics Evaluation and Research. FDA recommendations concerning testing for antibody to hepatitis B core antigen (Anti-HBc). [cited 2011 Jan 6]. Available from: URL http://www.fda.gov/downloads/BiologicsBloodVaccines/ GuidanceComplianceRegulatoryInformation/OtherRecommendationsforManufacturers/ MemorandumtoBloodEstablishments/UCM062847.pdf
12. Testung auf Antikörper gegen Hepatitis-B-Core-Antigen (anti-HBc) im Blutspendewesen. Bundesanzeiger 2006; 109: 4370.
13. Blood Products Advisory Committee. FDA's Current Thinking on Reentry of Donors Deferred for Repeated Detection of Antibody to Hepatitis B Core Antigen. October 21 2004. [cited 2011 Jan 6]. Available from: URL http://www.fda.gov/ ohrms/dockets/ac/04/briefing/2004-4074b1-01-topic%201.pdf
14. Food and Drug Administration. Center for Biologics Evaluation and Research. Requalification Method for Reentry of Blood Donors Deferred Because of Reactive Test Results for Antibody to Hepatitis B Core Antigen (Anti-HBc). May 2010. [cited 2011 Jan 6]. Available from: URL http://www.fda.gov/downloads/ BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Blood/ UCM210268.pdf
15. Schmidt M, Nübling CM, Scheiblauer H, Chudy M, Walch LA, Seifried E, Roth WK, Hourfar MK,. Anti-HBc screening of blood donors: a comparison of nine anti-HBc tests. Vox Sang 2006; 91: 237-43. (Pubitemid 44337281)
16. Hourfar MK, Walch LA, Geusendam G, Dengler T, Janetzko K, Gubbe K, Frank K, Karl A, Löhr M, Sireis W, Seifried E, Schmidt M,. Sensitivity and specificity of anti-HBc screening assays - which assay is best for blood donor screening? Int J Lab Hematol 2009; 31: 649-56.
17. Roth WK,. Hepatitis B and blood transfusion. ISBT Sci Ser 2007; 2: 178-83.
18. Niederhauser C, Mansouri Taleghani B, Graziani M, Stolz M, Tinguely C, Schneider P,. Blood donor screening: how to decrease the risk of transfusion-transmitted hepatitis B virus? Swiss Med Wkly 2008; 138: 134-41. (Pubitemid 351373909)
19. O'Brien SF, Fearon MA, Yi QL, Fan W, Scalia V, Muntz IR, Vamvakas EC,. Hepatitis B virus DNA-positive, hepatitis B surface antigen-negative blood donations intercepted by anti-hepatitis B core antigen testing: the Canadian Blood Services experience. Transfusion 2007; 47: 1809-15. (Pubitemid 47438546)
20. Jilg W, Hottenträger B, Weinberger K, Schlottmann K, Frick E, Holstege A, Schölmerich J, Palitzsch KD,. Prevalence of markers of hepatitis B in the adult German population. J Med Virol 2001; 63: 96-102. (Pubitemid 32142265)
21. Thierfelder W, Hellenbrand W, Meisel H, Schreier E, Dortschy R,. Prevalence of markers for hepatitis A, B, and C in the German population. Results of the German health interview and examination survey 1998. Eur J Epidemiol 2001; 17: 429-35. (Pubitemid 34105986)
22. Ollier L, Laffont C, Kechkekian A, Doglio A, Giordanengo V,. Detection of antibodies to hepatitis B core antigen using the Abbott ARCHITECT anti-HBc assay: analysis of borderline reactive sera. J Virol Methods 2008; 154: 206-9.
23. Brojer E, Grabarczyk P, Liszewski G, Mikulska M, Allain JP, Letowska M, Polish Blood Transfusion Service Viral Study Group. Characterization of HBV DNA+/HBsAg- blood donors in Poland identified by triplex NAT. Hepatology 2006; 44: 1666-74. (Pubitemid 44953671)
24. Allain JP,. Estimation of HBV transfusion risk. Transfusion 2009; 49: 1019-21.
25. Bremer CM, Saniewski M, Wend UC, Torres P, Lelie N, Gerlich WH, Glebe D,. Transient occult hepatitis B virus infection in a blood donor with high viremia. Transfusion 2009; 49: 1621-9.
26. Katz L, Strong DM, Tegtmeier G, Stramer S,. Performance of an algorithm for the reentry of volunteer blood donors deferred due to false-positive test results for antibody to hepatitis B core antigen. Transfusion 2008; 48: 2315-22.
27. Biswas R, Tabor E, Hsia CC, Wright DJ, Laycock ME, Fiebig EW, Peddada L, Smith R, Schreiber GB, Epstein JS, Nemo GJ, Busch MP,. Comparative sensitivity of HBV NATs and HBsAg assays for detection of acute HBV infection. Transfusion 2003; 43: 788-98. (Pubitemid 36629125)
28. Satake M, Taira R, Yugi H, Hino S, Kanemitsu K, Ikeda H, Tadokoro K,. Infectivity of blood components with low hepatitis B virus DNA levels identified in a lookback program. Transfusion 2007; 47: 1197-205. (Pubitemid 46934327)
29. Kleinman SH, Kuhns MC, Todd DS, Glynn SA, McNamara A, DiMarco A, Busch MP, Retrovirus Epidemiology Donor Study. Frequency of HBV DNA detection in US blood donors testing positive for the presence of anti-HBc: implications for transfusion transmission and donor screening. Transfusion 2003; 43: 696-704. (Pubitemid 36629113)
30. Kleinman SH, Strong DM, Tegtmeier GG, Holland PV, Gorlin JB, Cousins CR, Chiacchierini RP, Pietrelli LA,. Hepatitis B virus (HBV) DNA screening of blood donations in minipools with the COBAS AmpliScreen HBV test. Transfusion 2005; 45: 1247-57. (Pubitemid 41647787)
31. Kuhns MC, Kleinman SH, McNamara AL, Rawal B, Glynn S, Busch MP,; REDS Study Group. Lack of correlation between HBsAg and HBV DNA levels in blood donors who test positive for HBsAg and anti-HBc: implications for future HBV screening policy. Transfusion 2004; 44: 1332-9. (Pubitemid 39129246)
32. Marshall DA, Kleinman SH, Wong JB, AuBuchon JP, Grima DT, Kulin NA, Weinstein MC,. Cost-effectiveness of nucleic acid test screening of volunteer blood donations for hepatitis B, hepatitis C and human immunodeficiency virus in the United States. Vox Sang 2004; 86: 28-40. (Pubitemid 38200453)
33. Jackson BR, Busch MP, Stramer SL, AuBuchon JP,. The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations. Transfusion 2003; 43: 721-9. (Pubitemid 36629116)